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CONCLUSION:
Derivation and external validation of the SIMPLICITY Score as a simple 
immune-based risk score to predict infection in kidney transplant recipients.
The SIMPLICITY score, based on easily available
immune and clinical parameters, allows for
stratification of KT recipients according to their





Derivation Cohort (n = 410) Validation Cohort (n = 522)Construction of the risk score
• Retrospective analysis of prospectively 
assembled cohort
• Single center in Madrid (Spain)
• November 2008 and March 2013
• Study outcome: post-transplant infection 
between months 1 and 6
Time from transplantation (days) Time from transplantation (days)
Area under ROC curve = 0.774
Area under ROC curve = 0.730
• Prospective cohort
• 16 centers across Spain
• July 2014 to November 2015
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Abstract (250 words) 
Existing approaches for infection risk stratification in kidney transplant recipients are 
suboptimal. Here, we aimed to develop and validate a weighted score integrating non-
pathogen-specific immune parameters and clinical variables to predict the occurrence of 
post-transplant infectious complications. To this end, we retrospectively analyzed a 
single-center derivation cohort of 410 patients undergoing kidney transplantation in 
2008-2013 in Madrid. Peripheral blood lymphocyte subpopulations, serum 
immunoglobulin and complement levels were measured at one-month post-transplant. 
The primary and secondary outcomes were overall and bacterial infection through 
month six. A point score was derived from a logistic regression model and 
prospectively applied on a validation cohort of 522 patients undergoing kidney 
transplantation at 16 centers throughout Spain in 2014-2015. The SIMPLICITY score 
consisted of the following variables measured at month one after transplantation:  C3 
level, CD4+ T-cell count, CD8+ T-cell count, IgG level, glomerular filtration rate, 
recipient age, and infection within the first month. The discrimination capacity in the 
derivation and validation cohorts was good for overall (areas under the receiver 
operating curve of 0.774 and 0.730) and bacterial infection (0.767 and 0.734, 
respectively). The cumulative incidence of overall infection significantly increased 
across risk categories in the derivation (low-risk 13.7%; intermediate-risk, 35.9%; high-
risk77.6%) and validation datasets (10.2%, 28.9% and 50.4%, respectively). Thus, the 
SIMPLICITY score, based on easily available immune parameters, allows for 
stratification of kidney transplant recipients at month one according to their expected 
risk of subsequent infection. 
 




The occurrence of infectious complications is one of the major drawbacks with current clinical 
practices in solid organ transplantation (SOT).1 Despite its restrictive pharmacokinetic nature, 
therapeutic drug monitoring of immunosuppressive drugs constitutes the only approach widely 
used to investigate the state of post-transplant immunosuppression.2,3 An increasing number of 
immunological monitoring strategies have been proposed over the last years, ranging from the 
enumeration of non-pathogen-specific parameters (e.g. peripheral blood lymphocyte 
subpopulations [PBLSs]) to labor-consuming functional assays for pathogen-specific (e.g. 
cytomegalovirus [CMV]) cell-mediated immunity.4,5 Our group has previously demonstrated the 
value of post-transplant hypogammaglobulinemia (HGG), C3 hypocomplementemia (HCC) and 
low PBLS counts to identify kidney transplant (KT) recipients at increased risk of post-transplant 
infection.6-8 
Clinicians still face challenges in translating such biomarkers, which usually explore non-
overlapping effector immune mechanisms in a compartmentalized fashion, into daily practice. 
The integration of various easily available parameters covering innate and adaptive responses 
into a single risk score might provide a valuable support to the clinical decision-making process. 
Nevertheless, previous attempts to develop an immune-based score aimed at assessing the 
risk of infection after SOT have been of limited applicability due to the single-center design or 
small sizes of studies.9-16 Moreover, some of them incorporate complex assay procedures (such 
as T-cell proliferative responses) not always accessible to clinical laboratories.10,14 More 
importantly, none of these scores have been externally validated and, since the same datasets 
were usually used to derive prediction rules and to calculate diagnostic proprieties, 
overestimation of predictive capacity cannot be ruled out.17 
With these gaps in mind, our study was aimed at developing a weighted risk score based on 
simple non-pathogen-specific immune parameters and clinical variables to predict infection 
among KT recipients recruited in a single-center derivation cohort. We next assembled a large 
cohort at 16 Spanish centers to externally validate the predictive accuracy of the score. 
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Results 
Characteristics of derivation and validation cohorts 
Overall, 489 and 570 KT recipients were potentially eligible for inclusion in the derivation and 
validation cohorts. After screening assessment, 410 and 522 patients were finally included in 
each cohort, respectively (Figure S1 in Supporting Material). As expected in view of their 
different designs (single-center versus multicenter) and recruitment periods (2008-2013 and 
2014-2015, respectively), both cohorts differed in a number of characteristics, such as the 
proportion of participants with previous KT, age and type of donor, induction therapy, 
immunosuppressive regimen (mainly in the use of mammalian target of rapamycin [mTOR] 
inhibitors), and duration of anti-CMV prophylaxis (Table 1). 
One-year patient and death-censored graft survival in the derivation cohort were 91.4% and 
93.6%. The corresponding rates for the validation cohort were 97.6% and 97.1%, respectively. 
Three (0.7%) and 4 (0.8%) patients were lost to follow-up in each cohort before completing the 
6-month post-transplant period. 
Post-transplant infection in derivation and validation cohorts 
In the derivation cohort, 133 (32.4%) patients developed a total of 235 episodes of post-
transplant infection (primary study outcome [see definitions below]) between post-transplant 
months 1 and 6 (0.39 [95% confidence interval [CI]: 0.35 – 0.45] episodes per 100 patient-
years). Regarding the secondary outcome, 87 (21.2%) patients experienced 127 episodes of 
bacterial infection (0.24 [95% CI: 0.20 – 0.28] episodes per 100 patient-years) (Figure 1a). A 
detailed description of causative agents and clinical syndromes is provided as Supporting 
Material (Table S1). 
On the other hand, 105 (20.1%) patients in the validation cohort were diagnosed with 161 
separate episodes of infection between months 1 and 6 (0.21 [95% CI: 0.18 – 0.24] episodes 
per 100 patient-years), whereas 78 (14.9%) patients experienced 107 episodes of bacterial 
infection (0.14 [95% CI: 0.12 – 0.17] episodes per 100 patient-years) (Figure 1b). Causative 
agents and clinical syndromes are also detailed in Supporting Material (Table S2). 
Model derivation 
As expected from previous studies,6-8 patients in the derivation cohort that subsequently 
developed infection had lower PBLS counts and IgG and complement levels at month 1 
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compared to those who remained free from infection. Significant differences were found for 
CD3+ (P-value = 0.007), CD4+ (P-value = 0.025) and CD8+ T-cell counts (P-value = 0.004), and 
serum C3 levels (P-value = 0.0026) (Figure S2). Although IgG levels measured as a continuous 
variable did not significantly differ between patients with or without infection, a dose-response 
gradient in the cumulative incidence at month 6 was found across increasing degrees of IgG 
HGG (Figure S3). 
Since strong collinearity was found between the CD3+ T-cell count and the other PBLSs 
(variance inflation factor [VIF] values >3.5), this variable was not further considered for score 
construction. The following optimal cut-off values for predicting post-transplant infection were 
set according to the Youden's index18 for the remaining parameters: 40 cells/μL for CD4+ T-cell 
count, 155 cells/μL for CD8+ T-cell count, 500 mg/dL for serum IgG levels, and 78 mg/dL for 
serum C3 levels. 
We next explored in the derivation cohort the clinical (i.e. non-immune) variables available at 
post-transplant month 1 that predicted the development of infection (Table S3). Recipient age, 
underlying glomerulonephritis, donor age, donation after circulatory death donor, cold ischemia 
time, and infection and biopsy-proven acute graft rejection (BPAR) within the first month were 
identified as risk factors in the univariate analysis, whereas living donation and estimated 
glomerular filtration rate (eGFR) at month 1 revealed as protective factors. 
Construction of the risk score 
The logistic regression model of immune and clinical factors associated with the primary 
outcome is detailed in Table 2. Recipient and donor age showed strong multicollinearity 
(Pearson's r: 0.841, P-value <0.0001; VIF value: 3.417) and, therefore, only the former was kept 
into the model. Recipient age, cold ischemia time and eGFR were dichotomized at the optimal 
cut-off value for inclusion. The model showed good discriminative capacity (area under receiver 
operating characteristics curve [auROC]: 0.787; 95% CI: 0.737 – 0.838) and goodness-of-fit 
(Hosmer-Lemeshow test χ2 = 3.44; P-value = 0.904). 
As we aimed at constructing a user-friendly score based on the most parsimonious model that 
provided the best fit to the data, we explored a set of alternative simplified models. When cold 
ischemia time was removed to maintain only those clinical variables that are routinely available 
at month 1, the discriminative capacity was not meaningfully compromised (auROC: 0.781; 95% 
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CI: 0.731 – 0.831; Hosmer-Lemeshow test χ2 = 3.65; P-value = 0.888). 
Finally, we developed the SIMPLICITY (Seeking for Immune Status on Peripheral Blood 
Lymphocytes, Immunoglobulins and Complement Activity) score on the basis of three clinical 
variables (recipient age ≥62 years, eGFR <37 mL/min and previous infection) and four immune 
parameters (CD4+ T-cell count <40 cells/μL, CD8+ T-cell count <155 cells/μL, IgG levels <500 
mg/dL and C3 levels <78 mg/dL) measured at month 1. No relevant multicollinearity was found 
(all VIF values <1.5) (Table S4). Point scores assigned to the corresponding β regression 
coefficients are shown in Table 3. 
Performance of the risk score in the derivation cohort 
The SIMPLICITY score showed auROCs of 0.774 (95% CI: 0.718 – 0.823) and 0.767 (95% CI: 
0.706 – 0.827) for predicting overall (primary outcome) and bacterial infection (secondary 
outcome), respectively, between post-transplant months 1 and 6 (Figure 2). Internal validation 
by bootstrap resampling (1,000 iterations with 325 samples with replacement) revealed a stable 
discriminative capacity with marginal shrinkage (auROC for the primary outcome: 0.744 [95% 
CI: 0.689 – 0.793]). The donor/recipient (D/R) CMV serostatus had no meaningful impact on the 
score performance (auROC for D+/R- group: 0.821 [95% CI: 0.643 – 0.999]; auROC for R+ 
group: 0.775 [95% CI: 0.721 – 0.829]). 
The median score value was 5 (interquartile range [IQR]: 2 - 8). The diagnostic accuracy in 
terms of sensitivity, specificity, positive predictive value (PPV), negative predictive values 
(NPV), and likelihood ratios is shown in Table 4. For instance, a 70-year-old recipient with 30 
CD4+ T-cells/μL and a serum C3 level of 50 mg/dL at month 1 (score 10 [specificity of 94.9%]) 
would face a risk of developing infection through month 6 after transplantation (PPV) of at least 
77.6%. On the contrary, a 40-year-old patient with no previous history of post-transplant 
infection, normal graft function (eGFR of 65 mL/min), 100 CD4+ T-cells/μL, 80 CD8+ T-cells/μL, 
and neither HGG (IgG level of 700 mg/dL) nor HCC (C3 levels of 110 mg/dL) at month 1 (score 
2 [sensitivity of 91.8%]) would have a probability of remaining free from infection (NPV) of 
88.4%, although the risk of developing this outcome (PPV) would still be relatively high (38.8%). 
Overall, 177 (43.2%), 169 (41.2%) and 64 (15.6%) recipients were stratified into low-risk (score 
0-3), intermediate-risk (score 4-9) and high-risk (score ≥10) strata, respectively. The cumulative 
incidence of study outcomes through month 6 was significantly higher across increasing risk 
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strata, both for overall (low-risk [score 0-3]: 13.7%; intermediate-risk [score 4-9]: 35.9%; high-
risk [score ≥10]: 77.6%; P-value <0.0001) and bacterial infection (low-risk [score 0-3]: 7.5%; 
intermediate-risk [score 4-9]: 22.9%; high-risk [score ≥10]: 59.4%; P-value <0.0001) (Figure 3). 
The excess risk of overall infection associated with higher scores was confirmed after adjusting 
for the occurrence of BPAR through post-transplant month 6 as a time-dependent covariate 
(hazard ratio [HR] per one-point increment: 1.18; 95% CI: 1.50 – 1.23; P-value <0.0001), as well 
as in a set of sensitivity analyses (Figure 4). These results also applied to post-transplant 
bacterial infection (secondary outcome) (Figure S4). 
Performance of the risk score in the validation cohort 
Similarly to that observed in the derivation cohort, PBLS counts (CD3+, CD4+ and CD8+ T-cells) 
and serum C3 levels at post-transplant month 1 were significantly lower among patients with 
overall infection through month 6 compared to those without (Figure S5). 
The auROC of the SIMPLICITY score for predicting overall infection between post-transplant 
months 1 and 6 in the validation cohort was 0.730 (95% CI: 0.666 – 0.794), which was similar to 
that from the derivation dataset. The corresponding figure for bacterial infection was 0.734 (95% 
CI: 0.673 – 0.794) (Figure S6). The median score value was 3 (IQR: 0 - 6). The diagnostic 
accuracy (sensitivity, specificity, PPV, NPV and likelihood ratios) in the validation cohort is show 
in Table S5. Overall, 277 (53.1%), 190 (36.4%) and 55 (10.5%) patients were stratified into low-
risk (score 0-3), intermediate-risk (score 4-9) and high-risk (score ≥10) strata, respectively. The 
cumulative incidence of overall infection through post-transplant month 6 significantly increased 
across risk strata (low-risk [score 0-3]: 10.2%; intermediate-risk [score 4-9]: 28.9%; high-risk 
[score ≥10]: 50.4%; P-value <0.0001), with a comparable trend also evident for bacterial 
infection (low-risk [score 0-3]: 6.5%; intermediate-risk [score 4-9]: 23.2%; high-risk [score ≥10]: 
35.4%; P-value <0.0001) (Figure 5). The Hosmer-Lemeshow goodness-of-fit test confirmed 
that the score was well calibrated in the validation cohort (χ2 = 2.26; P-value = 0.689). 
The risk of developing infection between months 1 and 6 increased by 19% with each one-point 
increase in the SIMPLICTY score after adjusting for the occurrence of BPAR (HR [per one-point 
increment]: 1.19; 95% CI: 1.13 – 1.23; P-value <0.0001). Such a risk increase was similar for 
bacterial infection and across sensitivity analyses, although the association did not reach 
statistical significance for some specific causes of end-stage renal disease (ESRD) or CMV risk 
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categories (D+/R- serostatus) (Figure S7). 
Calibration of the risk score 
Hazard ratios for study outcomes across increasing categories of the SIMPLICITY score were in 
the same order of magnitude in both the derivation and validation cohorts (for example, 8.188 
and 6.922, respectively, for high-risk [score ≥10] versus low-risk [score 0-3] strata), indicating a 
robust capacity for risk stratification (Table S6). 
The calibration plot for predicting the primary outcome (Figure S8a) revealed a calibration 
intercept (β0) of -0.669 (95% bootstrap CI: -0.985 – -0.363), whereas the calibration slope was 
0.752 (95% bootstrap CI: 0.539 – 1.018) (Table S7). The intercept relates to calibration-in-the-
large, which compares the mean of all predicted risks with the mean observed risk.19 Since the 
95% CI of this estimate was negative, it could be deduced that the predicted probabilities were 
systematically too high. On the other hand, the calibration slope –which is related to the 
average strength of the predictor effects– did not significantly differ from 1.00, indicating that 
there was no evidence of average stronger or weaker effects in the derivation model. 
To investigate the cause of this suboptimal calibration, we calculated the mean and the SD of 
the linear predictor (LP) of the original model in both datasets. The LP results from the logit 
transformation of the predicted risks in logistic regression, with an increased (or decreased) 
variability of LP indicating more (or less) case-mix heterogeneity between derivation and 
validation cohorts. Conversely, the comparison of means of the LP reveals differences in 
outcome frequencies.20 Mean LP was higher in the derivation (-0.897) than in the validation 
dataset (-1.141), with similar SDs (1.177 and 1.114, respectively), which suggests that the 
calibration-in-the-large of the model in the external validation dataset would be mostly affected 
by differences in case mix-severity rather than by other sources of heterogeneity.20 
To overcome this circumstance, we explored to which extent an “updated” score would adjust 
better to differences in outcome incidence observed in the validation cohort. It has been shown 
that a prediction model may be updated (i.e. adjusted) to the new dataset obtained from a 
setting different from that in which it was originally developed.21,22 The updated model is 
simultaneously constructed on both the derivation and the validation data, yielding better risk 
estimates. After adjusting the intercept of the model, we obtained an alternative point 
assignment (Table S8). Predictive performance and calibration of this updated score are 
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available as Supporting Material (Figure S8b and Table S7). 
Imputation of missing data 
Finally, imputation of missing values for the continuous parameters included in the score 
(eGFR, CD4+ and CD8+ T-cell counts, and IgG and C3 levels) was performed in the derivation 
cohort, obtaining similar β regression coefficients (Table S9). The resulting model was then 
validated in four different imputed datasets, with auROC values for predicting the primary study 




Given the deleterious impact on graft and patient outcomes attributable to post-transplant 
infection, the development and validation of prediction rules able to effectively stratify the KT 
population according to individual susceptibility constitutes a crucial unmet clinical need. Herein, 
we propose the SIMPLICITY score, which integrates four non-pathogen-specific quantitative 
immune biomarkers (CD4+ and CD8+ T-cell counts and serum IgG and C3 levels) and three 
simple clinical variables (recipient age, prior infection and graft function). In contrast to previous 
efforts,9-16 our score has two major advantages. Firstly, the immune parameters included are 
broadly available in routine practice with a short turnaround time and no specialized laboratory 
equipment. Secondly, we have been able to validate the discriminative capacity and diagnostic 
accuracy of the score in an independent cohort recruited in 16 Spanish centers. 
From a practical point of view, a prediction rule for estimating the risk of infection after KT may 
be clinically implemented through two non-mutually exclusive approaches. On one hand, those 
recipients at low risk would benefit from the earlier discontinuation of anti-infective prophylaxis 
(such as valganciclovir or valacyclovir) or less close clinical monitoring, resulting in cost saving 
and reduction of associated adverse events (e.g. leukopenia). The safety of such strategy would 
be supported by the relatively high NPVs observed for patients with low scores. On the other 
hand, a multifaceted intervention based on the extension of prophylaxis, closer follow-up care or 
immune-targeted actions (such as intravenous or subcutaneous immunoglobulin replacement 
therapy in case of HGG) should be applied when the predicted infection risk is elevated. An 
alternative approach may consist of corticosteroid or tacrolimus tapering in recipients with 
evidence of over-immunosuppression. Furthermore, mTOR conversion may be considered due 
to the demonstrated decreaed risk of viral infection with these agents.23 By collapsing the 
SIMPLICITY score into three strata, we can define a low-risk population (score 0-3) in which the 
expected cumulative incidence of overall infection through month 6 would be below 15% (13.7% 
and 10.2% in the derivation and validation cohorts). Alternatively, KT recipients in the high-risk 
segment (score ≥10) face a cumulative risk of infection that exceeds 50%. The decision to 
categorize the score according to these thresholds was based on the low number of patients 
with very high values. In accordance with this observation, the score did not exhibit a normal 
distribution, with a median of 5 points and 3 points for the derivation and validation cohorts, 
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respectively. Future studies should estimate the equivalent to the “number necessary to treat”, 
or how many patients above the different score thresholds should receive extended prophylaxis 
or immunoglobulin therapy to prevent one additional episode of infection. 
The observed rates of infection during the post-transplant period were lower in the validation 
than in the derivation cohort and, therefore, the PPV for scores ≥10 differed across datasets. In 
view of the different recruitment periods (2008-2013 versus 2014-2015), such a discrepancy 
may be explained by long-term improvements in surgical procedures, immunosuppression and 
prophylaxis regimens. Even in the more contemporary period, in which a secular trend towards 
a sustained reduction in the incidence of infectious complications after KT has been 
suggested,24 the score was still able to identify a subgroup of recipients exposed to an 
unacceptable risk of severe, potentially life-threatening infection. By simply updating the 
intercept of the original model for differences in outcome frequency (a methodological approach 
increasingly used in clinical research21,22), we also propose an alternative “updated” score with 
improved calibration that could be applicable in settings with low a priori infection rates. 
Different prediction rules have been previously developed for the KT population. Blazik et al. 
created a “leukocyte phenotype and function (LPF) score” composed of CD4+ T-cell count, 
immunoglobulin levels, lymphoproliferative response to phytohaemagglutinin A, reactive oxygen 
species generation and neutrophil phagocytic function.10 In addition to the complex nature of the 
latter parameters, the derivation cohort only comprised 70 patients and no validation effort was 
made. Crepin et al. applied markers of immunosenescence (R+ CMV serostatus, CD4+/CD8+ 
ratio <1 and/or CD8+ T-cell count >700 cells/μL) to predict opportunistic and bacterial infection 
in a multicenter French cohort.13 However, no information on score performance was provided, 
and we were not able to externally validate the discriminative capacity of this immune risk 
phenotype.25 Dendle et al. have recently proposed a “level of immunosuppression score” (based 
on CD4+ T-cell and NK cell counts, graft function and use of mycophenolate mofetil) for 
predicting the occurrence of severe infection over the next 2 years. The resulting auROC was 
0.750, and the cumulative incidence of infection in patients classified within the highest risk 
category reached 84%.16 Nevertheless, this score still lacks external validation, and the 
inclusion criteria was restricted to patients at least at their third post-transplant month, which 
implies that the earlier period (with the highest incidence of infection) was not accounted for. 
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Regarding other SOT populations, Sarmiento et al. constructed an infection risk score for heart 
transplant recipients that included serum IgG levels <600 mg/dL at baseline or post-transplant 
day 7, serum C3 levels <80 mg/dL at day 7 and D/R CMV mismatch.14 Again, the authors did 
not supply data on the diagnostic accuracy. 
The SIMPLICITY score integrates into a single rule a number of immune parameters that have 
been already shown to predict infection after KT.6-8 Similarly to the well-established approach in 
human immunodeficiency virus (HIV) patients, post-transplant kinetics of CD4+ and CD8+ T-cell 
counts have been consistently correlated with the occurrence of opportunistic infection, 
including CMV disease and P. jirovecii pneumonia.26,27 Post-transplant HGG is a common and 
often neglected complication, with mild-to-severe forms occurring in as many as 39% and 15% 
of SOT recipients during the first year.28 Since the humoral response is responsible for the 
clearance of encapsulated bacteria through opsonization and complement activation, post-
transplant IgG HGG serves as a good predictor for bacterial infection.29 Finally, the C3 
component plays a pivotal role in the complement activation cascade to form the C5 convertase 
and to assemble the membrane attack complex.30 Therefore, the assessment of C3 HCC by 
nephelometry may advantageously replace more complex in vitro haemolytic assays to explore 
its functionality.11,31 It may be hypothesized that reductions in post-transplant 
immunosuppression would translate into subsequent normalization of these parameters and, 
eventually, decreasing score values. 
A number of limitations should be acknowledged. Our score was designed to predict exclusively 
the occurrence of infection beyond the first post-transplant month, despite the fact that earlier 
events (i.e. surgical site infection) can be also life-threating and increase hospital stay and 
costs. We have attempted at developing a comprehensive tool to predict any type of infection by 
combining a set of immune biomarkers with different pathophysiological significance, since they 
explore disparate compartments of the host response. The lack of an apparent impact on score 
performance of the use of antithymocyte globulin as induction therapy—a cause of profound 
lymphocytopenia— could be explained by this non-mechanistic approach. By excluding the 
explanatory variable “cold ischemia time” we gained in model simplicity at expense of losing 
some discriminative capacity. As previously noted, both cohorts differed in various clinical 
features (such as the frequency of previous KT, dialysis vintage, type of donor or duration of 
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anti-CMV prophylaxis). While such imbalances should have no relevance in the external 
validation process, which is aimed at demonstrating the discrimination and calibration of the 
score in an independent dataset not previously used to develop the model, the lower incidence 
of study outcomes in the validation cohort necessarily resulted in lower PPVs compared to the 
derivation cohort. Moreover, NPVs dot not exceed 90% even among low-risk categories, 
questioning the ability to effectively rule out the possibility of subsequent infection. Differences 
in clinical practices across participating centers might have led to some heterogeneity in event 
reporting, although this would have reinforced the external validity of the results. Finally, 
information on tacrolimus or mTOR inhibitor levels was not collected in the derivation dataset. 
In conclusion, we have developed and validated a prediction rule for post-transplant infection 
between months 1 and 6 after KT —the SIMPLICITY score— based of easily available immune 
(CD4+ and CD8+ T-cell counts and IgG and C3 levels) and clinical variables (recipient age, prior 
infection and graft function). This score offers the possibility to identify, as early as month 1, a 
subgroup of KT recipients at increased risk of subsequent infection that would benefit from 
individualized prevention strategies and tailoring of immunosuppression. Future intervention 
studies should be aimed at confirming the feasibility of this approach.  
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Methods 
Study population and setting 
The present observational derivation-validation study was performed in two non-overlapping 
cohorts. The first one (derivation cohort) comprised adult patients (≥18 years) with ESRD who 
consecutively underwent KT between November 2008 and March 2013 at the Hospital 
Universitario “12 de Octubre” (Madrid, Spain). The second, independent sequential cohort 
(validation cohort) comprised adult patients undergoing KT between July 2014 and November 
2015 at 16 Spanish transplant centers. Double organ recipients and those with HIV infection 
were excluded. 
All participants provided written informed consent at study entry, which was carried out in 
accordance with the ethical standards laid down in the Declarations of Helsinki and Istanbul. 
The study protocol (ClinicalTrials.gov identifier: NCT03083756) was approved by the Clinical 
Research Ethics Committee of the coordinating center (Hospital Universitario “12 de Octubre” 
[ref: 09/176]) and by local committees at other sites as required. This paper is compliant with 
the STROBE guidelines for observational studies. 
Study design 
All participants were enrolled at the time of KT and followed-up for 12 months, unless graft loss 
(retransplantation or permanent return to dialysis) or death occurred earlier. Patients were 
subjected to an immune status evaluation based on the enumeration of total lymphocyte and 
selected PBLS counts and the assessment of serum immunoglobulins and complement levels 
at pre-established time points (months 1 and 6 after transplantation). Pre-transplant, peri-
operative and post-transplant variables were prospectively collected by local investigators in an 
anonymized manner using a standardized case report form and entered into a secure electronic 
database. In addition to the usual follow-up at each center, study visits were scheduled at 
baseline and post-transplant months 1, 3, 6 and 12. 
We focused on infectious complications occurring between months 1 and 6 since the overall 
amount of immunosuppression usually peaks during this intermediate post-transplant period, as 
does the risk of overall and, particularly, opportunistic infection. On the other hand, surgical 
factors and donor-derived infections rather than host’s response play a predominant role during 
the earlier period (first post-transplant month).32 The primary study outcome was the occurrence 
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of overall infection throughout the intermediate post-transplant period (months 1 to 6 after 
transplantation). Bacterial infection during such period was analyzed as a secondary outcome. 
Immune status evaluation 
Whole blood samples were collected into EDTA-containing Vacutainer tubes and analyzed 
within 18-24 hours in the laboratories of the participating centers. PBLS counts (CD3+, CD4+ 
and CD8+ T-cells) were assessed by means of an automated multicolor flow cytometry system. 
The 6-color BD Multitest system was used at the coordinating center, with acquisition performed 
on the BD FACSCanto II instrument using BD FACSCanto clinical software (all from BD 
Biosciences, San Jose, CA). Comparable methods were used in the remaining study sites. 
Serum immunoglobulin (IgG, IgA and IgM) and complement (C3 and C4) levels were measured 
by nephelometry (Image-System, Beckman Coulter GmbH, Krefeld, Germany, or similar). 
Study definitions 
Post-transplant infection was defined by any of the following: (a) isolation of an unequivocally 
pathogenic microorganism from any sample; (b) isolation of any microorganism from a clinically 
relevant sample obtained under sterile conditions; (c) isolation of a potentially pathogenic 
microorganism from any sample accompanied by signs and/or symptoms of local or systemic 
infection; and/or (d) clinical data suggestive of infection without microbiological isolation and 
complete resolution on antimicrobial therapy. To be analyzed as study outcome the episode 
should have required hospitalization and/or administration of intravenous therapy. Opportunistic 
infections typically indicative of excessive immunosuppression (such as mucosal herpes 
simplex virus reactivation or shingles) were also counted as study outcome regardless of the 
requirement for hospitalization. 
Specific infectious syndromes were diagnosed on the basis of commonly accepted criteria.33-36 
CMV disease included viral syndrome and end-organ disease defined as per the American 
Society of Transplantation criteria.37 Proven or probable invasive fungal infection was defined 
according to the European Organization on Research and Treatment in Cancer and the 
Mycoses Study Group criteria.38 The eGFR was assessed by the 4-variable Modification of Diet 
in Renal Disease equation.39 The occurrence of BPAR was suspected in case of an otherwise 
unexplained rise in serum creatinine and diagnosed by histological examination.40 
Statistical analysis 
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Quantitative data were shown as the mean ± standard deviation or the median with IQR. 
Qualitative variables were expressed as absolute and relative frequencies. Categorical 
variables were compared using the χ2 test. Student’s t-test or Mann-Whitney U test were 
applied for continuous variables, as appropriate. Pearson's correlation coefficient or Spearman's 
rank correlation coefficient were used to investigate the correlation between continuous 
variables. 
A weighted score was created to predict the occurrence, in the derivation cohort, of the primary 
outcome between post-transplant months 1 to 6 on the basis of the immune status evaluation 
performed at month 1 and on the clinical parameters available at that point. To be included in 
either the derivation or validation cohort, the patient had to be alive and with functioning graft at 
month 1. Observation was censored at the time of diagnosis of the first episode of infection, 
post-transplant month 6 or lost to follow-up. No imputation for missing data was performed. 
Multivariate analysis was used to identify immunological and clinical variables associated with 
the occurrence of the study outcome in the derivation cohort. Variables with univariate P-values 
≤0.1 were entered into a logistic regression model in a backward stepwise selection fashion. 
Continuous variables were dichotomized according to the optimal cut-off value, as determined 
by the Youden's index.18 The Hosmer-Lemeshow test was used to assess the goodness-of-fit of 
the models. Discriminative capacity was estimated by the auROC. Multicollinearity among 
explanatory variables was analyzed using the VIF, with values <3 being considered acceptable. 
The most parsimonious model (i.e. the highest outcome variability explained with the lowest 
number of variables) was selected for the construction of the score. 
The weighted risk score for predicting overall infection between post-transplant months 1 to 6 
(primary outcome) was derived from the point estimate for each variable using the β coefficients 
of the final model. Relative point values were assigned by dividing each regression coefficient 
by one-half of the smallest coefficient and rounding to the nearest integer. The resulting score 
was first internally validated by means of the bootstrap method in 1,000 iterations with 325 
samples drawn with replacement from the original derivation dataset. Diagnostic accuracy was 
assessed by sensitivity, specificity, PPV, NPV and likelihood ratios using different risk cutoff 
scores. 
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Time-to-event curves were plotted by the Kaplan-Meier method and inter-group differences 
were compared with the log-rank test to analyze the ability of the score for stratification across 
increasing risk categories. Univariate and multivariate Cox regression models were constructed 
to investigate whether the associations found between score risk categories and outcomes 
remained significant after adjusting for clinical covariates, with associations expressed HRs and 
95% CIs. To show robustness of the score, a set of sensitivity analyses restricted to specific 
causes of ESRD, D/R CMV serostatus, or immunosuppression or prophylaxis regimens was 
also performed. All these validation analyses were also carried out for post-transplant bacterial 
infection (secondary outcome). 
The resulting score was next applied to the independent external validation cohort to assess its 
discriminative capacity (auROC), diagnostic accuracy and calibration. Calibration indicates how 
closely predicted probabilities match observed frequencies of occurrence, and was graphically 
assessed by means of calibration plots. 
Finally, we performed a sensitivity analysis by imputing missing data with a chained equation 
approach. The number of imputations to add was four. For the process of model construction, 
continuous variables with missing values were imputed and then dichotomized using original 
cut-off values. The regression coefficients were re-estimated for each of the four datasets. The 
same approach was applied for the validation process. In each of these imputed datasets, the 
discrimination capacity of the original model was estimated by means of auROC values. 
All the significance tests were two-tailed. The threshold for significance was set at a P-value 
<0.05. Statistical analysis was performed with SPSS version 20.0 (IBM Corp., Armonk, NY), 
STATA version 16.0 (StataCorp, College Station, TX), and R software version 3.4.2 (R 
Foundation for Statistical Computing, Vienna, Austria).41 Graphs were generated with Prism 
version 6.0 (GraphPad Software Inc., La Jolla, CA). 
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Tables 
Table 1. Demographics and main clinical characteristics of derivation and validation cohorts. 
Variable 
Derivation cohort 
(n = 410) 
Validation cohort 
(n = 522) 
P-value 
Age of recipient, years [mean ± SD] 54.9 ± 14.9 55.6 ± 13.4 0.483 
Gender of recipient (male) [n (%)] 254 (62.0) 343 (65.7) 0.263 
Previous kidney transplantation [n (%)] 82 (20.0) 59 (11.3) 0.0003 
Underlying end-stage renal disease [n (%)]    
Glomerulonephritis 90 (22.0) 129 (24.7) 0.363 
Diabetic nephropathy 72 (17.6) 74 (14.2) 0.187 
Policystosis 54 (13.2) 90 (17.2) 0.106 
Nephroangiosclerosis 52 (12.7) 41 (7.9) 0.019 
Chronic interstitial nephropathy 36 (8.8) 35 (6.7) 0.289 
Congenital nephropathy 18 (4.4) 12 (2.3) 0.108 
Reflux nephropathy 15 (3.7) 6 (1.1) 0.019 
Obstructive nephropathy 3 (0.7) 11 (2.1) 0.149 
Unknown 35 (8.5) 101 (19.3) 0.0001 
Other 35 (8.5) 28 (5.4) 0.075 
CMV serostatus [n (%)]    
D+/R+ 274 (76.3) 360 (69.0) 0.533 
D-/R+ 54 (15.0) 74 (14.2) 0.729 
D+/R- 27 (6.6) 49 (9.4) 0.153 
D-/R- 4 (1.0) 16 (3.1) 0.051 
D unknown/R+ 51 (12.4) 23 (4.4) 0.0001 
Positive HCV serostatus [n (%)]  33 (8.0) 21 (4.0) 0.014 
Positive HBsAg status [n (%)] 1 (0.7) 13 (2.5) 0.005 
Pre-transplant renal replacement therapy [n (%)] 386 (94.1) 472 (90.4) 0.049 
Hemodialysis 332 (80.9) 366 (70.1) 0.0002 
Continuous ambulatory peritoneal dialysis 54 (13.2) 106 (22.5) 0.005 
Time on dialysis, months [median (IQR)] 21.3 (10.8 – 43.1) 25.0 (13.0 – 43.8) 0.050 
Age of donor, years [mean ± SD] 53.4 ± 16.5 55.5 ± 14.9 0.036 
Gender of donor (male) [n (%)] 267 (65.1) 279 (53.4) 0.0004 
Type of donor [n (%)]    
DBD donor 263 (64.1) 413 (79.1) 0.0001 
DCD donor 135 (32.9) 51 (9.8) 0.0001 
Living donor 12 (2.9) 58 (11.1) 0.0001 
Cold ischemia time, hours [median (IQR)] 17.9 (11.5 – 22.0) 15.0 (9.3 – 20.0) <0.0001 
Induction therapy [n (%)]a    
ATG 206 (50.2) 186 (35.6) 0.0001 
Basiliximab 137 (33.4) 241 (46.2) 0.0001 
Eculizumab 0 (0.0) 5 (1.0) 0.071 
None 67 (16.3) 95 (18.2) 0.512 
Primary immunosuppression regimen [n (%)]a    
Steroids 404 (98.5) 519 (99.4) 0.193 
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Tacrolimus 406 (99.0) 520 (99.6) 0.414 
Cyclosporine 0 (0.0) 2 (0.4) 0.507 
Mycophenolate mofetil/mycophenolic acid 364 (88.8) 415 (79.5) 0.0002 
Azathioprine 42 (10.2) 8 (1.5) 0.0001 
mTOR inhibitor 2 (0.5) 99 (18.9) 0.0001 
Anti-CMV prophylaxis [n (%)] 206 (50.2) 335 (64.2) 0.0001 
Prophylaxis for 3 months 178 (43.4) 136 (26.1) 0.0001 
Prophylaxis for ≥3 months 28 (6.8) 178 (34.0) 0.0001 
Anti-Pneumocystis prophylaxis [n (%)] 393 (95.6) 407 (78.0) 0.0001 
Non-infectious complications [n (%)]    
Delayed graft function 249 (60.7) 160 (30.7) 0.0001 
New-onset diabetes 57 (13.9) 28 (5.4) 0.0001 
BPAR within the first post-transplant year 75 (18.3) 70 (13.4) 0.051 
≥2 episodes 7 (1.7) 6 (1.1) 0.577 
Time from transplantation to the first 
episode, days [median (IQR)] 
30.0 (14.0 – 115.0) 19.5 (11.0 – 135.0) 0.458 
Infection (≥1 episode) within the first post-
transplant month [n (%)]b 
76 (18.5) 86 (16.5) 0.461 
eGFR at month 1, mL/min [mean ± SD] 41.2 ± 20.6 43.9 ± 21.7 0.057 
eGFR at month 6, mL/min [mean ± SD] 49.6 ± 20.2 48.7 ± 19.4 0.509 
ATG: antithymocyte globulin; BPAR: biopsy-proven acute graft rejection; CMV: cytomegalovirus; D: donor; DBD: 
donation after brain death; DCD: donation after circulatory death; eGFR: estimated glomerular filtration rate; HBsAg: 
hepatitis B virus surface antigen; HCV: hepatitis C virus; IQR: interquartile range; KT: kidney transplantation; mTOR: 
mammalian target of rapamycin; R: recipient; SD: standard deviation. 
a The sum of percentages exceeds 100% since some patients received more than one drug. 
b Includes 81 episodes in the derivation cohort (incisional surgical site infection [n = 24], acute graft pyelonephritis [n 
= 21], gastrointestinal infection [n = 10], skin and soft-tissue infection [n = 6], catheter-related bloodstream infection [n 
= 5], pneumonia [n = 4], intraabdominal infection [n = 3], primary bloodstream infection [n = 3], CMV viral syndrome [n 
= 2], and other [n = 3]) and 86 episodes in the validation cohort (acute graft pyelonephritis [n = 51], incisional surgical 
site infection [n = 11], gastrointestinal infection [n = 7], catheter-related bloodstream infection [n = 6], pneumonia [n = 
4], skin and soft-tissue infection [n = 3], CMV viral syndrome [n = 2], intraabdominal infection [n = 1] and primary 
bloodstream infection [n = 1]). 
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Table 2. Derivation cohort: Multivariate logistic regression analysis of variables predicting overall infection between post-transplant months 1 and 6. 
 Univariate  Multivariate 
OR 95% CI P-value  OR 95% CI P-value 
Recipient age ≥62 years 3.08 2.00 – 4.75 <0.0001  2.67 1.53 – 4.65 0.010 
Glomerulonephritis as ESRD 0.48 0.28 – 0.84 0.009  – – – 
DCD donor 0.59 0.38 – 0.95 0.028  – – – 
Living donor 0.96 0.93 – 0.98 0.011  – – – 
Cold ischemia time >19.5 hours 2.28 1.49 – 3.48 0.0001  1.99 1.13 – 3.53 0.018 
eGFR (at month 1) <37 mL/min 3.42 2.21 – 5.27 <0.0001  1.99 1.18 – 3.34 0.010 
Infection within the first month 2.69 1.62 – 4.48 <0.0001  2.38 1.31 – 4.35 0.005 
BPAR within the first month 2.55 1.29 – 4.99 0.007  – – – 
CD4+ T-cell count (at month 1) <40 cells/μL 2.46 1.41 – 4.27 0.001  2.47 1.15 – 5.33 0.021 
CD8+ T-cell count (at month 1) <155 cells/μL 2.38 1.54 – 3.68 0.0001  1.83 0.99 – 3.39 0.053 
Serum IgG levels (at month 1) <500 mg/dL 2.18 1.18 – 4.03 0.013  1.97 0.96 – 4.05 0.066 
Serum C3 levels (at month 1) <78 mg/dL 4.55 2.47 – 8.38 <0.0001  3.38 1.62 – 7.06 0.001 
BPAR: biopsy-proven acute graft rejection; CI: confidence interval; DCD: donation after circulatory death; eGFR: estimated glomerular filtration rate; 
ESRD: end-stage renal disease; IgG: immunoglobulin G; OR: odds ratio. 
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Table 3. SIMPLICITY score: point assignment based on the regression coefficients obtained for 
the variables selected in the final multivariable logistic regression model in the derivation cohort. 
Variable 
β regression 
coefficient (95% CI) 
Score 
Recipient age ≥62 years 0.94 (0.36 – 1.50) 3 
eGFR at month 1 <37 mL/min 0.69 (0.18 – 1.23) 3 
Infection within the first post-transplant montha 0.85 (0.25 – 1.46) 3 
CD4+ T-cell count (at month 1) <40 cells/μL 0.94 (0.17 – 1.70) 3 
CD8+ T-cell count (at month 1) <155 cells/μL 0.56 (-0.07 – 1.18) 2 
Serum IgG levels (at month 1) <500 mg/dL 0.71 (-0.03 – 1.44) 3 
Serum C3 levels (at month 1) <78 mg/dL 1.14 (0.39 – 1.88) 4 
Intercept (β0) -2.08 (-2.13 – -2.03) – 
CI: confidence interval; eGFR: estimated glomerular filtration rate; IgG: immunoglobulin G. 
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Table 4. Derivation cohort: Diagnostic accuracy of the SIMPLICITY score at month 1 for predicting overall infection between post-transplant months 1 and 6 





Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) PLR (95% CI) NLR (95% CI) 
Score ≥0 100.0 100.0 (97.0 – 100.0) 0.0 (0.0 – 1.5) 32.5 (32.5 – 32.5) NA 1.00 (1.00 – 1.00) NA 
Score ≥2 77.1 91.8 (85.4 – 96.0) 30.0 (24.5 – 36.1) 38.8 (36.5 – 41.1) 88.4 (80.3 – 93.4) 1.31 (1.19 – 1.45) 0.27 (0.15 – 0.51) 
Score ≥4 56.8 81.9 (73.9 – 88.3) 55.3 (48.9 – 61.6) 46.9 (42.9 – 50.9) 86.4 (81.1 – 90.4) 1.84 (1.56 – 2.15) 0.33 (0.22 – 0.48) 
Score ≥6 44.5 72.9 (64.2 – 80.6) 69.2 (63.1 – 74.8) 53.3 (47.9 – 58.6) 84.1 (79.7 – 87.8) 2.37 (1.91 – 2.93) 0.39 (0.29 – 0.53) 
Score ≥8 27.5 52.5 (43.2 – 61.6) 84.6 (79.5 – 88.8) 62.1 (54.0 – 69.6) 78.7 (75.3 – 81.8) 3.40 (2.44 – 4.75) 0.56 (0.46 – 0.68) 
Score ≥10 15.5 36.9 (28.3 – 46.1) 94.9 (91.4 – 97.2) 77.6 (66.0 – 86.1) 75.7 (73.1 – 78.2) 7.18 (4.03 – 12.80) 0.67 (0.58 – 0.76) 
Score ≥12 7.2 19.7 (13.0 – 27.8) 98.8 (96.6 – 99.8) 88.9 (71.1 – 96.3) 71.8 (70.0 – 73.6) 16.59 (5.09 – 54.03) 0.81 (0.74 – 0.89) 
Score ≥14 3.7 9.8 (5.2 – 16.6) 99.2 (97.2 – 99.9) 85.7 (57.7 – 96.4) 69.5 (68.3 – 70.8) 12.44 (2.83 – 54.73) 0.91 (0.86 – 0.96) 
CI: confidence interval; NA: not applicable; NLR: negative likelihood ratio; NPV: negative predictive value; PLR: positive likelihood ratio; PPV: positive predictive value. 
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Figure legends 
• Figure 1. Kaplan-Meier curves of cumulative incidence of overall and bacterial infection 
(continuous and dotted lines, respectively) between post-transplant months 1 and 6 in the 
derivation (a) and validation cohorts (b). 
• Figure 2. Derivation cohort: Discriminative capacity, as assessed by the area under receiver 
operating characteristics curves (auROCs) and 95% confidence intervals (CIs), of the 
SIMPLICITY score at month 1 to predict the occurrence of overall (a) and bacterial infection 
(b) between post-transplant months 1 and 6. 
• Figure 3. Derivation cohort: Kaplan-Meier cumulative incidence curves of overall (a) and 
bacterial infection (b) between post-transplant months 1 and 6 according to increasing risk 
categories of the SIMPLICITY score. 
• Figure 4. Derivation cohort: Hazard ratios (HRs) with 95% confidence intervals (CIs) for the 
occurrence of overall infection between post-transplant months 1 and 6 according to the 
SIMPLICITY score at month 1. ATG: antithymocyte globulin; BPAR: biopsy-proven acute 
graft rejection; CMV: cytomegalovirus; DBD: donation after brain death; DCD: donation after 
circulatory death; ESRD: end-stage renal disease. 
• Figure 5. Validation cohort: Kaplan-Meier cumulative incidence curves of overall (a) and 
bacterial infection (b) between post-transplant months 1 and 6 according to increasing risk 
categories of the SIMPLICITY score. 
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Supporting Material 
• Supplementary Results: 
o Table S1. Derivation cohort: Clinical syndromes and causative agents involved in 235 
episodes of infection between post-transplant months 1 and 6. 
o Table S2. Validation cohort: Clinical syndromes and causative agents involved in 161 
episodes of infection between post-transplant months 1 and 6. 
o Table S3. Derivation cohort: Univariate analysis of clinical (i.e. non-immune) variables 
predicting the development of post-transplant infection between months 1 and 6. 
o Table S4. Derivation cohort: Variance inflation factors assessed to control for 
multicollinearity among the explanatory variables included in the predictive model. 
o Table S5. Validation cohort: Diagnostic accuracy of the SIMPLICITY score at month 1 for 
predicting overall infection between post-transplant months 1 and 6 (primary outcome). 
o Table S6. Hazard ratios across SIMPLICITY score risk categories for overall and bacterial 
infection between post-transplant months 1 and 6 in the derivation and validation cohorts. 
o Table S7. Predictive performance and calibration parameters of the SIMPLICITY score. 
o Table S8. Updated SIMPLICITY score: the intercept (β0) of the original model has been 
updated according to the dataset derived from the validation cohort, resulting in alternative 
point assignment. 
o Table S9. Missing data imputation for model construction: Regression coefficients 
obtained for the variables selected in the final logistic regression model after imputation of 
missing values in the derivation cohort. 
o Table S10. Missing data imputation for model validation: Diagnostic accuracy for 
predicting overall infection between post-transplant months 1 and 6 (primary outcome) in 
each of the four imputed datasets. 
o Figure S1. Patient flow diagram. 
o Figure S2. Derivation cohort: Peripheral blood lymphocyte subpopulations and serum IgG 
and complement levels measured at post-transplant month 1 according to the occurrence 
of infection between months 1 and 6. 
o Figure S3. Derivation cohort: Cumulative incidence of post-transplant infection at month 6 
according to the degree of IgG hypogammaglobulinemia at month 1. 
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o Figure S4. Derivation cohort: Hazard ratios for the occurrence of bacterial infection 
between post-transplant months 1 and 6 according to the SIMPLICITY score at month 1. 
o Figure S5. Validation cohort: Peripheral blood lymphocyte subpopulations and serum IgG 
and complement levels measured at post-transplant month 1 according to the occurrence 
of infection between months 1 and 6. 
o Figure S6. Validation cohort: Discriminative capacity assessed by the area under receiver 
operating characteristics curves (auROCs) of the SIMPLICITY score at month 1 to predict 
overall (a) and bacterial infection (b) between post-transplant months 1 and 6. 
o Figure S7. Validation cohort: Hazard ratios for the occurrence of overall (a) and bacterial 
infection (b) between post-transplant months 1 and 6 according to the SIMPLICITY score 
at month 1. 
o Figure S8. Calibration plot comparing observed and predicted probabilities of overall 
infection between post-transplant months 1 and 6 in the validation dataset for the original 
(a) and updated models (b) of the SIMPLICITY score. 
Supplementary information is available on Kidney International's web site. 






